Witryna16 kwi 2015 · Germany-based Isarna Therapeutics has started the first-in-human Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting TGF-β2, for the treatment of advanced glaucoma. WitrynaISTH0036 is a 14-mer phosphorothioate Locked Nucleic Acid- (LNA) modified antisense oligonucleotide gapmer, targeting the sequence of TGF-β2 mRNA and was developed for therapeutic intervention in ocular diseases. It was shown to effectively and potently downregulate target
First-in-human phase I study of ISTH0036, an antisense ... - PubMed
Witryna15 gru 2016 · ISTH0036 is a 14-mer phosphorothioate Locked Nucleic Acid- (LNA) modified antisense oligonucleotide gapmer, targeting the sequence of TGF-β2 mRNA and was developed for therapeutic intervention in ocular diseases. It was shown to effectively and potently downregulate target mRNA in a dose-dependent manner in … Witryna31 sie 2024 · Isarna Therapeutics will present an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2024. Prof ... compass law beenleigh
First-in-human phase I study of ISTH0036, an antisense ... - PLOS
WitrynaIsarna Therapeutics GmbH 279 obserwujących na LinkedIn. Developing first in class antisense therapies for blockbuster retina indications. Isarna Therapeutics is a clinical stage biotech company, headquartered in Munich, Germany. Isarna develops ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in the … WitrynaNEW YORK, April 12, 2024 /PRNewswire/ -- The open-angle glaucoma therapeutics market size is forecasted to increase by USD 2.58 billion from 2024 to 2026, at a CAGR of 7.18%, according to the recent market study by Technavio.The growth of the market will be driven by the promising pipeline and recent approvals, increasing demand for … Witryna15 lis 2024 · ISTH0036 is a locked nucleic acid (LNA)-modified antisense oligonucleotide developed by ISARNA Therapeutics to selectively target the mRNA of TGF-β2 and was evaluated for its therapeutic potential in a murine model of glaucoma filtration surgery. Glaucoma filtration surgery is a common procedure that drains the aqueous humor to … compass language log level 6 pdf